Boston Scientific Announces Completion Of Enrollment In Aneurysm Coiling Clinical Trial

< BACK TO INTERNATIONAL starstarstarstarstar   Culture - International Press Release
6th January 2010, 05:03am - Views: 879





Culture International Boston Scientific Corporation 1 image

Culture International Boston Scientific Corporation 2 image










MEDIA RELEASE PR37555


Boston Scientific Announces Completion of Enrollment in Aneurysm Coiling Clinical

Trial


NATICK, Mass., Jan. 5 /PRNewswire-AsiaNet/ --


    Boston Scientific Corporation (NYSE: BSX) today announced that it has

completed enrollment in its MAPS(TM) clinical trial, which is studying the

coiling of intracranial aneurysms. This prospective, randomized trial

commenced enrollment in 2007 and has reached its goal of 630 patients,

enrolled at 47 hospitals in 11 countries. Principal investigators for the

trial are Anil Gholkar, O.B.E., M.B.B.S., Clay Johnston, M.D., Ph.D., and

Cameron McDougall, M.D.


    The MAPS trial compares clinical outcomes in patients treated with either

bare-platinum GDC(R) Detachable Coils or Matrix2(R) Detachable Coils, which

are covered with a bio-polymer. The primary endpoint is Target Aneurysm

Recurrence (TAR) at one year, a composite clinical endpoint of target

aneurysm rupture or re-rupture, re-treatment or neurologic death. Secondary

angiographic endpoints will be compared to the primary clinical outcomes over

several years to evaluate the long-term predictive value of 12-month

angiography.


    "The MAPS trial has significant potential to enhance our understanding of

the products we use to treat intracranial aneurysms as well as our methods

for assessing outcomes," said Dr. Gholkar. "By conducting rigorous

measurement, monitoring and adjudication of clinical outcomes over multiple

years, the MAPS trial will establish a critical baseline from which to judge

existing treatments as well as future endovascular technologies."


    Aquilla Turk, D.O., is the Chairman of the MAPS Steering Committee and

enrolled the final patient in the trial. "With enrollment completed, our

focus now turns to data monitoring, completion of follow up and preparation

for primary endpoint publication in 2011," said Dr. Turk. "The Steering

Committee is grateful to all the trial investigators who have worked so

diligently to reach this milestone."


    "This important trial is the latest example of Boston Scientific's 24

years of collaboration and leadership in the field of neurointervention and

lays the groundwork for continued advances in the minimally invasive

treatment of brain aneurysms," said Mark Paul, President of Boston

Scientific's Neurovascular business. "We appreciate the participation of the

124 physicians and 63 research coordinators, whose efforts led to the

successful completion of enrollment."


    For more information on the MAPS Trial visit:



    Boston Scientific is a worldwide developer, manufacturer and marketer of

medical devices whose products are used in a broad range of interventional

medical specialties. For more information, please visit:



    Cautionary Statement Regarding Forward-Looking Statements


Culture International Boston Scientific Corporation 3 image

    This press release contains forward-looking statements. Boston Scientific

wishes to caution the reader of this press release that actual results may

differ from those discussed in the forward-looking statements and may be

adversely affected by, among other things, risks associated with new product

development and commercialization, clinical trials, intellectual property,

regulatory approvals, competitive offerings, Boston Scientific's overall

business strategy, and other factors described in Boston Scientific's filings

with the Securities and Exchange Commission.


    CONTACT: Geraldine Varoqui

             Boston Scientific

             Public Relations International

             +49 170 782 85 58

             varoquig@bsci.com



SOURCE: Boston Scientific Corporation


    CONTACT: Geraldine Varoqui, 

             Boston Scientific, 

             Public Relations International, 

             +49-170-782-85-58,  

             varoquig@bsci.com


Translations:




To view this and other AsiaNet releases please visit http://www.asianetnews.net






news articles logo NEWS ARTICLES
Contact News Articles |Remove this article